Covaxin’s both dose 50 percent effective on symptomatic Covid patients: Study


New Delhi: The threat of Coronavirus Pandemic in the whole world including India is not over yet. Patients infected with Kovid (COVID-19) are still coming out. However, the pace of Corona has slowed down. In the midst of all this, big information has come out about Covaxin. Want to tell you that both the doses of Covaxin are 50 percent effective in symptomatic (patients with symptoms) of Covid.

It is to be known that both the doses of vaccine are 50 percent effective in the symptomatology of corona. This claim has been made in the study. This claim has been made in the Real World Assessment of Indian Vaccine published in The Lancet Infectious Disease Journal. These things have come to the fore in a recent peer-review published in The Lancet.

It should be noted that this study has been done on 2714 health workers from April 15 to May 15 in AIIMS, Delhi. These people had symptoms of the corona. Along with this, their RT-PCR test was also done. If the report is to be believed, then this study was done when there was an orgy of delta variant in India and it was confirmed in 80 percent of the corona cases.


Covaxin is jointly developed by the Indian Council of Medical Research and the National Institute of Virology. Along with this, Bharat Biotech has acquired the SARS-COV-2 strain through collaboration. Both doses of Covaxin are given to people at an interval of 28 days. Earlier in January this year, Covaxin has been allowed for emergency use in people above 18 years of age in India.